TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-Positive Breast Cancer
Interventions: DRUG: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
Sponsor: Guangdong Provincial People's Hospital